Venkat Jasti

Suven gets product patents for neuro-degenerative drug

In a BSE filing today, Suven Life said it has been granted "one process patent from Europe, one process patent from Japan and one process patent from New Zealand corresponding to the New Chemical Entities (NCEs) which are for the treatment of disorders associated with Neurodegenerative diseases".

Suven Life gets NCEs' patents from Israel, Macau and South Korea

These patents are valid through 2032, the Hyderabad- based company said in a statement.

Suven begins clinical trial of antidepressant

In a BSE filing, Suven Life Sciences said its NCESUVN- 911, a "novel chemical entity intended for the treatment of major depressive disorder (MDD) has initiated Phase 1 development and first dosing... and the topline results from the study is expected during the quarter Jan-March 2018".

Will India's search for a blockbuster drug end at Suven?

Suven‘s efforts to make its research pay dividends will bear fruit if its molecule SUVN-502, now getting tested on patients in the United States, manages to demonstrate safety and efficacy in patients.

To maintain EBITDA margins at 32%, topline 10-15%: Suven Life

Venkat Jasti, Chairman and CEO, Suven Life Sciences is confident of maintaining EBITDA margins at 32 percent or more. He is also confident of 10-15 percent topline growth in FY17 and FY18.

Suven gets 2 patents for molecules targeting CNS disorder

The company has been granted "one product patent from India and one from Japan corresponding to the new chemical entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases...," Suven Life Sciences said in a filing to BSE.

Maintain base business revenue guidance of 15% in FY17: Suven

The Contract Research and Manufacturing Services (CRAMS) side of the business has contributed to the June quarter bottomline on the back of good product mix, says Venkat Jasti, CEO, Suven Life Sciences.

Suven Life Sciences gets patent for neuro-degenerative drug

In a BSE filing today, Suven Life said it has been granted "one product patent from Europe and two product patents from Eurasia corresponding to New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases".

Suven Life gets patents for neuro-degenerative drug

In a regulatory filing today, Suven Life said it has "secured product patents in Australia, Eurasia, Israel and the US to their New Chemical Entities (NCEs) for CNS therapy through mechanism of action".

Suven Life gets patent for neuro-degenerative drug

The company has been granted "one product patent from China, one product patent from Eurasia and one product patent from Hong Kong corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neuro-degenerative diseases", it said in a BSE filing. The patents will be valid till 2032.

Suven Life gets patent for neuro-degenerative drug

In a BSE filing today, Suven Life said it has been granted "one product patent from Australia and one product patent from Canada corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases".

Target over 20% revenue growth in FY17: Suven Lifesciences

Venkat Jasti, chairman and chief executive officer, Suven Lifesciences says FY17 looks to be a more promising year and he hopes to log a revenue growth of 20 percent in the same year.

Suven Life gets patents for neurodegenerative drug

In a BSE filing, the company said it has been granted "two product patents from Canada and one product patent from China corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases." These patents are valid through 2029 and 2030, the company added.

Suven Life gets patents for neurodegenerative drug

Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's

Suven Life Sciences gets patents for neurodegenerative drug

Biopharmaceutical firm Suven Life Sciences on Tuesday said it has been granted one patent each by the US, Israel and Macau for a drug used in the treatment of neurodegenerative diseases.

Suven Life Sciences gets patents for neurological drug

Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's. In a BSE filing, the company said it has been granted "one product patent from Europe and one product patent from Hong Kong corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".

Suven Life gets patents for molecules in three countries

These patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts, Suven said.

Suven Life gets patent for neuro-degenerative drug

Drug firm Suven Life Sciences has been granted a patent each by the US and New Zealand for a drug used in the treatment of neuro-degenerative diseases. The patents are valid until 2030 and 2031, respectively, Suven Life Sciences said in a filing to the BSE.

Suven Life up 5%, gets product patent in Eurasia & Israel

Shares of Suven Life Sciences (Suven) climbed 5 percent intraday Monday on getting product patent each in Eurasia and Israel.

Suven gets patent for neurodegenerative drug in 4 countries

Neurodegenerative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are useful in treatment of cognitive impairment associated with neurodegenerative disorders.